Cellectis: TAL-effector Nuclease: Issuance by the USPTO of Two New Patents

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US patents (US 8,440,431 and US 8,440,432) directed to TAL-effector nucleases.

Help employers find you! Check out all the jobs and post your resume.

Back to news